Loading
No insider purchase over the last 90 days. The latest, by GEHL KEITH M, was filed 07 Apr 2025.
Kewaunee Scientific Corp /DE/: what insiders have been doing
This page follows insider dealings at Kewaunee Scientific Corp /DE/ as filed with SEC (Form 4), a company from the Industry sector. Over the twelve months to 22 October 2026, 11 filings were filed, from 4 insiders.
There is no open-market purchase to report; the filings show 7 sales worth €250k by 2 insiders. One trade stands out by size: a sale of €70k from Hull Thomas David III, disclosed on 8 January 2026.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (3,171 companies, median 24 filings), a count of 11 filings is below the norm. Our records for Kewaunee Scientific Corp /DE/ go back to 2016, with 16 purchases and 62 sales on the open market in total. For the fiscal year to 30 April 2026, the annual 10-K puts revenue at 282.0 m USD and net income at 9.6 m USD.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
376
Thresholds
n/a
Buy Volume
€471,885
16 ops. · all time
Sell Volume
€3M
62 ops. · all time
Who traded when
BuySaleThomas David Hull III18 sales
Donald T. Gardner III16 sales
Elizabeth D. Phillips3 sales
Keith M. Gehl3 buys
Douglas J. Batdorff1 sale
Ryan S. Noble1 sale
Since the insiders bought
- -0.7%Entry US$34.94 · Close at T+365 US$34.71
- +125.4%Entry US$24.18 · Close at T+365 US$54.50
- +15.4%Entry US$10.60 · Close at T+365 US$12.23
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 3,504 of 26,280 companies
71.4
score / 100
Value88
Quality55
FCF yld16%
Earn yld10%
EV/EBITDA5.2x
ROE13%
Gross mgn29%
Net mgn3.4%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended April 2026 · cache
US$32.39
Analyst consensus
Income statement
RevenueUS$282M
Gross profitUS$80.4M29% margin
EBITDAUS$23.9M8% margin
Net incomeUS$9.6M3.0% margin
Valuation
PER (trailing)11.7x
P/Book1.3x
Beta0.76
Balance sheet & cash
Market capUS$93.8M
Total debtUS$30.2M
Free Cash FlowUS$14.7M
Debt / Equity72%
Profitability & ownership
ROE12.5%
ROA5.1%
% insiders24.4%
% institutions41.7%
Last declaration on 2 July 2026
Declarations376 total
7,451 sharesCommon StockSEC:0001814145-26-000004:0
5,609 sharesCommon StockSEC:0001814145-26-000004:1
851 sharesCommon StockSEC:0001814145-26-000004:2
2,750 shares0Common StockSEC:0001261869-26-000002:0
2,177 shares@ US$37.508.1% of flowCommon StockSEC:0001657070-26-000004:0
2,000 shares@ US$37.5712.3% of flowCommon StockSEC:0001775052-26-000002:0
629 shares@ US$37.660.9% of flowCommon StockSEC:0001657070-26-000002:1
29 shares@ US$38.000.1% of flowCommon StockSEC:0001657070-26-000002:0
884 shares@ US$38.013.3% of flowCommon StockSEC:0001657070-25-000026:0
1,000 shares@ US$39.003.9% of flowCommon StockSEC:0001657070-25-000024:0
1,000 shares@ US$39.003.9% of flowCommon StockSEC:0001657070-25-000022:0
3,000 shares@ US$42.7621.2% of flowCommon StockSEC:0001775052-25-000017:0
3 shares@ US$44.200.0% of flowCommon StockSEC:0001467437-25-000008:1
1,000 shares@ US$43.094.3% of flowCommon StockSEC:0001657070-25-000020:0
6,877 shares@ US$43.2045.2% of flowCommon StockSEC:0001467437-25-000008:0
1,854 shares@ US$43.428.0% of flowCommon StockSEC:0001657070-25-000018:0
1,000 shares@ US$43.621.6% of flowCommon StockSEC:0001657070-25-000016:1
721 shares@ US$44.003.1% of flowCommon StockSEC:0001657070-25-000016:0
773 shares@ US$45.341.3% of flowCommon StockSEC:0001657070-25-000014:1
652 shares@ US$46.003.0% of flowCommon StockSEC:0001657070-25-000014:0
690 shares0Common StockSEC:0002084386-25-000004:0
325 shares0Common StockSEC:0001261869-25-000006:0
904 shares@ US$59.183.7% of flowCommon StockSEC:0001775052-25-000012:1
2,096 shares@ US$58.3419.9% of flowCommon StockSEC:0001775052-25-000012:0
879 shares@ US$58.348.3% of flowCommon StockSEC:0001814145-25-000006:1
25 of 376 declarations
About Kewaunee Scientific Corp /DE/
Kewaunee Scientific Corp /DE/ (ticker: KEQU) is a U.S.-listed industrial company traded on NASDAQ in the United States. Founded in 1906, Kewaunee has built a long-standing niche in the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. For French-speaking investors, it is best viewed as a specialized capital-goods supplier with exposure to structural spending in scientific, educational, healthcare, and research facilities rather than as a broad-based general manufacturer.
The company’s core product set includes steel and wood casework, laboratory benches, epoxy resin work surfaces and sinks, fume hoods, adaptable modular systems, moveable workstations, and biological safety cabinets. Beyond the physical furniture line, Kewaunee also provides installation and related project services, which makes its model more integrated than a pure product seller. Its end markets span life sciences, education, government, healthcare, and general research. This end-market mix gives Kewaunee a degree of resilience, since demand is tied to laboratory build-outs, renovations, compliance-driven upgrades, and scientific infrastructure investment.
Read moreShow less
Kewaunee’s headquarters are in Statesville, North Carolina. The company also maintains sales offices in the United States, India, Saudi Arabia, and Singapore, with manufacturing facilities in Statesville and Bangalore, India. That footprint gives Kewaunee a dual identity: a U.S.-anchored industrial base with a meaningful international reach, especially across Asia and into other overseas markets. The company’s local manufacturing presence in India also supports regional customer needs and broadens its ability to serve markets beyond North America.
Competitive positioning is driven by specialization, technical credibility, and a reputation for meeting demanding safety and quality standards in laboratory environments. Kewaunee emphasizes collaboration with industry bodies to help shape product standards, which supports its positioning as a trusted supplier in a technically regulated niche. Recent developments have been especially important. In fiscal 2025, Kewaunee reported annual sales of $240.5 million, up 18% year over year, alongside stronger EBITDA performance. A key strategic milestone was the November 1, 2024 acquisition of Nu Aire, which expands the product portfolio into biological safety cabinets, CO2 incubators, ultra-low freezers, and adjacent lab products. Management also reported a backlog of $214.6 million as of April 30, 2025, indicating solid near-term demand visibility. Overall, KEQU looks like a small-cap industrial compounder with a focused market position, acquisition-led growth, and long-duration exposure to laboratory capex cycles in the United States and abroad.
